Canaccord Genuity Maintains Buy on TELA Bio, Lowers Price Target to $12

Written by Emily J. Thompson, Senior Investment Analyst

TELA-2.14%

Source: Newsfilter

Updated: Aug 13 2024

0mins

Source: Newsfilter

TELA

$0.9589+Infinity%1D

Analyst Views on TELA

Wall Street analysts forecast TELA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TELA is 3.31 USD with a low forecast of 1.25 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Analyst Rating

3 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.980

Low

1.25

Averages

3.31

High

5.00

Current: 0.980

Low

1.25

Averages

3.31

High

5.00

Canaccord

Buy

downgrade

$7 -> $4

2025-11-18

Reason

Canaccord

Price Target

$7 -> $4

AI Analysis

2025-11-18

downgrade

Buy

Reason

Canaccord lowered the firm's price target on Tela Bio (TELA) to $4 from $7 and keeps a Buy rating on the shares. The firm said they posted a challenged Q3 as it missed top-line expectations and lowered full-year guidance, though it reiterated confidence in its commercial strategy and sales force structure as recent hires Jeffrey Blizzard and Jim Hagen from Abiomed (ABMD) become increasingly important pieces to the Tela Bio story.

Citizens JMP

Outperform

NULL

downgrade

$7 -> $5

2025-11-14

Reason

Citizens JMP

Price Target

$7 -> $5

2025-11-14

downgrade

Outperform

NULL

Reason

Citizens JMP lowered the firm's price target on Tela Bio to $5 from $7 and keeps an Outperform rating on the shares. Quarterly sales were shy of the Street by about 5%, reflecting several meaningful highlights, such as strong international sales and the addition of new customers, the analyst tells investors in a research note. The cons outweighed the pros, and management lowered its top-line guidance by 9% year over year, the firm adds.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TELA

Unlock Now

Piper Sandler

Matt O'Brien

Neutral

downgrade

2025-11-14

Reason

Piper Sandler

Matt O'Brien

Price Target

2025-11-14

downgrade

Neutral

Reason

Piper Sandler analyst Matt O'Brien lowered the firm's price target on Tela Bio to $1.25 from $2 and keeps a Neutral rating on the shares. The firm notes the company reported Q3 results which missed its estimate on the top-line and on the operating loss side of things. Revenue guidance for the year was lowered, which is certainly a disappointing update, Piper adds.

Canaccord Genuity

Caitlin Cronin

Strong Buy

Maintains

$12 → $7

2025-03-21

Reason

Canaccord Genuity

Caitlin Cronin

Price Target

$12 → $7

2025-03-21

Maintains

Strong Buy

Reason

Canaccord lowered the firm's price target on Tela Bio to $7 from $12 and keeps a Buy rating on the shares. The firm said they posted a tough quarter significantly below consensus revenues as it lost a number of sales reps to competitors in the Q4 with the sales org already lean post commercial streamlining in the Q3. While the Q4 was a challenging one, the management team are experienced MedTech operators, and Canaccord believes they would need to see sustained sales org churn before becoming materially less constructive.

About TELA

TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.